Browsing Tag

Nasdaq:AVEO

U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application…

Eli Pacheco Oct 13, 2022 0

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a…

Health

AVEO Oncology to Announce Second Quarter 2022 Financial Results on August 4, 2022

Eli Pacheco Jul 29, 2022 0

BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report second quarter…

Health

AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA®…

Eli Pacheco Jun 21, 2022 0

BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer…

Health

AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of…

Eli Pacheco Feb 15, 2022 0

Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib) Long-term data from pivotal TIVO-3 study…

Health

AVEO Oncology Announces Participation at the H.C. Wainwright Virtual BioConnect 2022…

Eli Pacheco Dec 23, 2021 0

BOSTON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior…